Journal: Frontiers in Bioengineering and Biotechnology

Article Title: Magnetically driven hydrogel microrobots for enhancing the therapeutic effect of anlotinib on osteosarcoma

doi: 10.3389/fbioe.2024.1409988

Figure Lengend Snippet: The combined use of Anlotinib and SCR1481B1 effectively enhances the inhibitory effect on tumor cells in vitro . (A) The combined application of Anlotinb and MET inhibitor (SCR1481B1) exhibits a synergistic effect on HOS and DuNN osteosarcoma cells. (B) The protein expression levels and quantitative analysis of VEGFR2 and MET in HOS osteosarcoma cell after in vitro treatment with the combination of Anlotinb and MET inhibitor (SCR1481B1) . (C) In vitro clonogenic assay and quantitative analysis of the colony formation were performed among osteosarcoma cell lines treated with the combination of Anlotinb and MET inhibitor (SCR1481B1). (**** p < 0.0001).

Article Snippet: The reagents used in the study included SCR1481B1 (# HY-18711A, United States) and Anlotinib (Selleck #S8726, CN).

Techniques: In Vitro, Expressing, Clonogenic Assay

Journal: Frontiers in Bioengineering and Biotechnology

Article Title: Magnetically driven hydrogel microrobots for enhancing the therapeutic effect of anlotinib on osteosarcoma

doi: 10.3389/fbioe.2024.1409988

Figure Lengend Snippet: The orchestration of a targeted drug conveyance mechanism facilitated by the utilization of magnetic-driven hydrogel microrobots. (A) This study utilizes droplet microfluidic technology to construct gelatin microrobots. In the realm of droplet microfluidics, droplet formation is primarily governed by the interplay of tension differences between the continuous and dispersed phase fluids. The combined effect of surface tension and shear forces at the interface of these two phases gives rise to droplets. The accompanying figure presents a schematic representation of the fabrication of gelatin microspheres via a flow-focusing device. Created with BioRender.com. (B) Size distribution chart of Magnetic-driven hydrogel microrobot particles. (C) Motion rate characteristics of Magnetic-driven hydrogel microrobots at frequencies from two to 52Hz under different magnetic field densities. (D) Optical and fluorescence microscopy images of magnetic-driven hydrogel microrobots loaded with or without Anlotinib and MET inhibitor (SCR1481B1). The scale bar is 400 μm.

Article Snippet: The reagents used in the study included SCR1481B1 (# HY-18711A, United States) and Anlotinib (Selleck #S8726, CN).

Techniques: Construct, Shear, Fluorescence, Microscopy

Journal: Frontiers in Bioengineering and Biotechnology

Article Title: Magnetically driven hydrogel microrobots for enhancing the therapeutic effect of anlotinib on osteosarcoma

doi: 10.3389/fbioe.2024.1409988

Figure Lengend Snippet: Motion characteristics, controllable flexible motion performance and drug release performance of drug-loaded Magnetic-driven hydrogel microrobots. (A) Schematic illustration of tumor destruction mediated by a drug-loaded delivery system facilitated by magnetic-driven hydrogel microrobots. Created with BioRender.com (B) Controllable motion modes of Magnetic-driven hydrogel microrobots without drug loading. Controllable motion modes of Anlotinb-loaded Magnetic-driven hydrogel microrobots. Controllable motion modes of SCR1481B1-loaded Magnetic-driven hydrogel microrobots. Controllable motion modes of Magnetic-driven hydrogel microrobots loaded with Anlotinib and SCR1481B1. The scale bar is 100 μm. (C) Schematic illustration of drug release from drug-loaded Magnetic-driven hydrogel microrobots (Created with BioRender.com ) and optical microscopy and fluorescence microscopy images of drug release from drug-loaded Magnetic-driven hydrogel microrobots. The scale bar is 100 μm.

Article Snippet: The reagents used in the study included SCR1481B1 (# HY-18711A, United States) and Anlotinib (Selleck #S8726, CN).

Techniques: Microscopy, Fluorescence

Journal: Frontiers in Bioengineering and Biotechnology

Article Title: Magnetically driven hydrogel microrobots for enhancing the therapeutic effect of anlotinib on osteosarcoma

doi: 10.3389/fbioe.2024.1409988

Figure Lengend Snippet: Drug-loaded Magnetic-driven hydrogel microrobots exhibit potent cytotoxicity against osteosarcoma cells (under both two-dimensional and three-dimensional cell culture conditions) through the release of drugs. (A) Representative optical and fluorescence microscope images of osteosarcoma cells under two-dimensional culture conditions following a combined treatment regimen with Anlotinb and SCR1481B1. Calcein/AM-PI double staining was conducted to detect the cytotoxic effects exerted by both unloaded Magnetic-driven hydrogel microrobots and drug-loaded Magnetic-driven hydrogel microrobots on osteosarcoma cells. The magnification is 100 times. The scale bar is 250 μm. (B) Representative optical and fluorescence microscope images of osteosarcoma cells under three-dimensional culture conditions after combined treatment with Anlotinb and SCR1481B1. The magnification is 100 times. The scale bar is 250 μm.

Article Snippet: The reagents used in the study included SCR1481B1 (# HY-18711A, United States) and Anlotinib (Selleck #S8726, CN).

Techniques: Cell Culture, Fluorescence, Microscopy, Double Staining

Journal: Frontiers in Oncology

Article Title: Targeting liposarcoma: unveiling molecular pathways and therapeutic opportunities

doi: 10.3389/fonc.2024.1484027

Figure Lengend Snippet: Clinical trials related to LPS-targeted therapy.

Article Snippet: ALTER-0202 (NCT01878448) , Anlotinib , A multikinase angiogenesis inhibitor , II , 166 STS pts , LPS (n = 13) , PFR12 weeks , – , LPS PFR 12weeks:63% LPS mPFS:5.6m LPS mOS:13 m LPS ORR:7.7% , Yihebali Chi , 2018 , ( ) .

Techniques: Clinical Proteomics, Activity Assay

Journal: Frontiers in Oncology

Article Title: Targeting liposarcoma: unveiling molecular pathways and therapeutic opportunities

doi: 10.3389/fonc.2024.1484027

Figure Lengend Snippet: Clinical trials of LPS-targeted and immunotherapy are currently underway.

Article Snippet: ALTER-0202 (NCT01878448) , Anlotinib , A multikinase angiogenesis inhibitor , II , 166 STS pts , LPS (n = 13) , PFR12 weeks , – , LPS PFR 12weeks:63% LPS mPFS:5.6m LPS mOS:13 m LPS ORR:7.7% , Yihebali Chi , 2018 , ( ) .

Techniques: Clinical Proteomics, Bioprocessing, Blocking Assay, Expressing, Activity Assay

Journal: Clinical Cancer Research

Article Title: Phase II Study of TQB2450, a Novel PD-L1 Antibody, in Combination with Anlotinib in Patients with Locally Advanced or Metastatic Soft Tissue Sarcoma

doi: 10.1158/1078-0432.CCR-22-0871

Figure Lengend Snippet: Kaplan–Meier estimates for PFS ( A ) and OS ( B ) in all patients. Anlo+TQB, Anlotinib+TQB2450.

Article Snippet: Anlotinib (AL3818) is a multitarget tyrosine kinase inhibitor (TKI) against both tumor angiogenesis and tumor cell proliferation that acts by targeting VEGFR, FGFR, platelet-derived growth factor receptor, and c-Kit simultaneously ( ).

Techniques:

Journal: Oncotarget

Article Title: Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies

doi: 10.18632/oncotarget.8203

Figure Lengend Snippet: Clinical trials related to FGF2/FGFR pathway

Article Snippet: Phase II, open-label study of Lucitanib in patients with FGFR1-driven lung cancer (NCT02109016) , 40 , Apr 2014/ recruiting - ongoing , Advenchen Laboratories (Moorpark, CA) , Clovis Oncology, Inc. (Boulder, CO) , FGFR 1-3 inhibitor; VEGFR1-3 inhibitor , Interventional, efficacy (objective response rate).

Techniques: Clinical Proteomics, Amplification, Drug discovery

Journal: iScience

Article Title: Cutoff value of IC 50 for drug sensitivity in patient-derived tumor organoids in colorectal cancer

doi: 10.1016/j.isci.2023.107116

Figure Lengend Snippet:

Article Snippet: Anlotinib Dihydrochloride , GLPBIO , GC25073; CAS: 1360460-82-7.

Techniques: Recombinant, Software

Journal: Cell Death & Disease

Article Title: Directly targeting c-Myc contributes to the anti-multiple myeloma effect of anlotinib

doi: 10.1038/s41419-021-03685-w

Figure Lengend Snippet: A Chemical structure of anlotinib. B MM cell lines (NCI-H929, RPMI-8226, LP1, MM.1S, OPM2, and U266) were treated with anlotinib (0–20 μM) for 48 h, and the cell viability was detected by CCK8. The IC50 value was calculated based on the dose–response curve using Prism 8.0 software. C – E NCI-H929, RPMI-8226 and LP1 cells were treated with anlotinib for 24 and 48 h, followed by the assessment of cell viability. F The CD138 + and G CD138 − cells isolated from MM patients were treated with anlotinib (0–10 μM) for 24 h, and then the cell viability was assessed. H Normal BMMCs from four healthy donors were treated with anlotinib (0–10 μM) for 24 h. Data are shown as mean ± SD and representative of three independent experiments.

Article Snippet: Anlotinib, CHX and MG-132 were purchased from CSNpharm (Chicago, IL, USA), dissolved in Dimethyl Sulfoxide (Sigma, St. Louis, MO) and stored in dark at −20 °C until use.

Techniques: Software, Isolation

Journal: Cell Death & Disease

Article Title: Directly targeting c-Myc contributes to the anti-multiple myeloma effect of anlotinib

doi: 10.1038/s41419-021-03685-w

Figure Lengend Snippet: A , B NCI-H929 and RPMI-8226 cells were co-cultured with or without BMSCs, and then treated with anlotinib (0–10 μM) for 48 h. After staining with Annexin V and PI, flow cytometry analysis was performed to assess the apoptosis rate. C , D NCI-H929 and RPMI-8226 cells were treated with anlotinib (0–10 μM) for 48 h, in the presence or absence of IL-6 (10 ng/ml). Cell proliferation was measured by CCK-8 assay. ** P < 0.01; *** P < 0.001; NS P > 0.05. Data are shown as mean ±SD and from three independent experiments.

Article Snippet: Anlotinib, CHX and MG-132 were purchased from CSNpharm (Chicago, IL, USA), dissolved in Dimethyl Sulfoxide (Sigma, St. Louis, MO) and stored in dark at −20 °C until use.

Techniques: Cell Culture, Staining, Flow Cytometry, CCK-8 Assay

Journal: Cell Death & Disease

Article Title: Directly targeting c-Myc contributes to the anti-multiple myeloma effect of anlotinib

doi: 10.1038/s41419-021-03685-w

Figure Lengend Snippet: A NCI-H929 and RPMI-8226 cells were treated with 5 µM anlotinib for the indicated time. Cell cycle was analyzed by flow cytometry. The numerical percentage shown indicates the G 2 /M population. B The morphology of NCI-H929 and RPMI-8226 cells after anlotinib treatment (5 μM, 24 h) was observed by Wright staining. Scale bar: 20 μm. C Representative images of TUNEL and DAPI staining for cells treated with anlotinib (5 μM, 24 h). The green dot represents positive TUNEL staining. The blowup images from the red boxes showed a significant fraction of nuclei after anlotinib exposure. Scale bar: 20 μm. D NCI-H929 and RPMI-8226 cells were treated with anlotinib (0–10 μM) for 24 h. Whole cell lysates were subjected to western blotting using antibodies against PARP-1, caspase 3, caspase 9, and β-actin. E Cells were treated as described in D , and apoptosis was detected by flow cytometry using Annexin V/PI staining. The percentages of apoptotic cells were shown in the histogram from three independent experiments. Each experiment was performed in triplicate. Con: control group; Anlo: anlotinib group. *** P < 0.001.

Article Snippet: Anlotinib, CHX and MG-132 were purchased from CSNpharm (Chicago, IL, USA), dissolved in Dimethyl Sulfoxide (Sigma, St. Louis, MO) and stored in dark at −20 °C until use.

Techniques: Flow Cytometry, Wright Stain, TUNEL Assay, Staining, Western Blot, Control

Journal: Cell Death & Disease

Article Title: Directly targeting c-Myc contributes to the anti-multiple myeloma effect of anlotinib

doi: 10.1038/s41419-021-03685-w

Figure Lengend Snippet: A Volcano plot of the DEGs from the transcriptomes of the control and anlotinib group ( P < 0.05, Fold change > 1.5). B KEGG analysis of the DEGs. C NCI-H929 and RPMI-8226 cells were treated with anlotinib (5 μM) for the indicated time. Whole cell lysates were subjected to western blotting. D Heatmaps of the top 40 downregulated c-Myc target genes in NCI-H929 cells treated with anlotinib versus DMSO for 12 h. Rows show Z -scores are calculated for each cell type. E NCI-H929, RPMI-8226, and LP1 cells were treated with the indicated concentration of anlotinib for 24 h or 5 μM anlotinib for the indicated time. Whole cell lysates were subjected to western blotting using c-Myc and β-actin antibodies. Con control group, Anlo anlotinib group. The experiments were performed in triplicate.

Article Snippet: Anlotinib, CHX and MG-132 were purchased from CSNpharm (Chicago, IL, USA), dissolved in Dimethyl Sulfoxide (Sigma, St. Louis, MO) and stored in dark at −20 °C until use.

Techniques: Control, Western Blot, Concentration Assay

Journal: Cell Death & Disease

Article Title: Directly targeting c-Myc contributes to the anti-multiple myeloma effect of anlotinib

doi: 10.1038/s41419-021-03685-w

Figure Lengend Snippet: A NCI-H929 cells were treated with CHX (10 μg/ml) in the presence or absence of anlotinib (5 μM) for the indicated time. The levels of c-Myc protein were evaluated and plotted in the graph. B NCI-H929 and RPMI-8226 cells were treated with either anlotinib (5 μM) and/or MG132 (5 μM) for 6 h, and then the c-Myc protein was assessed by western blotting. C NCI-H929 cells were pretreated with 5 μM MG132 for 3 h and then incubated with 5 μM anlotinib for 3 h. The cell lysates were immunoprecipitated with anti-c-Myc antibody and then probed with anti-ubiquitin antibody. D , E The binding between anlotinib and c-Myc protein was examined by the CETSA method at different temperatures or doses. The indicated proteins were evaluated by western blotting (left). CETSA curves of c-Myc were determined in the absence and presence of anlotinib. Each band intensity of c-Myc in DMSO or anlotinib group was normalized with respect to that obtained at the lowest temperature or dose (right). F Whole cell lysates of NCI-H929 cells were incubated with anlotinib followed by digestion with pronase according to the “Materials and methods” section. Then, the degree of c-Myc degradation was determined by western blot. G , H Overexpression and shRNA knockdown efficiency of c-Myc in NCI-H929 cells was measured by western blotting analysis. The effects of c-Myc knockdown or overexpression on cell apoptosis were evaluated by flow cytometry. The presented columns are given as the means ± SD. Statistically significant values compared with the DMSO group or empty vector group are depicted by * or # , respectively. *** P < 0.001, # P < 0.05, and ### P < 0.001. Con control group, Anlo anlotinib group. Data are shown as mean ± SD and representative of three independent experiments.

Article Snippet: Anlotinib, CHX and MG-132 were purchased from CSNpharm (Chicago, IL, USA), dissolved in Dimethyl Sulfoxide (Sigma, St. Louis, MO) and stored in dark at −20 °C until use.

Techniques: Western Blot, Incubation, Immunoprecipitation, Ubiquitin Proteomics, Binding Assay, Over Expression, shRNA, Knockdown, Flow Cytometry, Plasmid Preparation, Control

Journal: Cell Death & Disease

Article Title: Directly targeting c-Myc contributes to the anti-multiple myeloma effect of anlotinib

doi: 10.1038/s41419-021-03685-w

Figure Lengend Snippet: A NCI-H929, NCI-H929-BR, MM.1S, and MM.1S-BR cells were treated with various concentrations of bortezomib for 24 h. Cell viability was measured by CCK8 assay. B NCI-H929-BR and MM.1S-BR cells were treated with anlotinib (0–20 µM) for 24 and 48 h, followed by an assessment of cell viability. C NCI-H929-BR and MM.1S-BR cells were treated with 5 µM anlotinib for 8 h. The cell cycle was analyzed by flow cytometry. D The morphology of NCI-H929-BR and MM.1S-BR cells after anlotinib treatment (5 μM, 8 h) was observed using Wright staining. E Apoptosis of cells treated with 5 µM anlotinib for 24 h was detected by flow cytometry using Annexin V/PI staining. F NCI-H929-BR and MM.1S-BR cells were treated with anlotinib (5 μM) for the indicated time. Whole cell lysates were subjected to western blotting. G The combined effects of anlotinib and bortezomib in NCI-H929 cells were assessed using the CompuSyn software. Con: control group; Anlo: anlotinib group. *** P < 0.001. Each experiment was performed in triplicate.

Article Snippet: Anlotinib, CHX and MG-132 were purchased from CSNpharm (Chicago, IL, USA), dissolved in Dimethyl Sulfoxide (Sigma, St. Louis, MO) and stored in dark at −20 °C until use.

Techniques: CCK-8 Assay, Flow Cytometry, Wright Stain, Staining, Western Blot, Software, Control

Journal: Cell Death & Disease

Article Title: Directly targeting c-Myc contributes to the anti-multiple myeloma effect of anlotinib

doi: 10.1038/s41419-021-03685-w

Figure Lengend Snippet: A Nude mice bearing subcutaneous NCI-H929 tumors were treated with either anlotinib (3 mg/kg) or vehicle control by intragastric administration for consecutive 14 days. Tumor size was measured every 2 days. B The tumor tissues were excised and weighed on day 14. C Gross appearance of the tumors. D The weight of mice was monitored every 2 days. E Representative IHC staining of tumor tissues. Scale bars: 50 μM. F Tumor tissues were lysed and subjected to western blotting to detect the protein level of c-Myc. Con control group, Anlo anlotinib group. ** P < 0.01, *** P < 0.001.

Article Snippet: Anlotinib, CHX and MG-132 were purchased from CSNpharm (Chicago, IL, USA), dissolved in Dimethyl Sulfoxide (Sigma, St. Louis, MO) and stored in dark at −20 °C until use.

Techniques: Control, Immunohistochemistry, Western Blot

Journal: Canadian Respiratory Journal

Article Title: Anlotinib Inhibits Cisplatin Resistance in Non-Small-Cell Lung Cancer Cells by Inhibiting MCL-1 Expression via MET/STAT3/Akt Pathway

doi: 10.1155/2024/2632014

Figure Lengend Snippet: Anlotinib regulates DDP resistance in NSCLC cells. (a) The viability of A549, A549/DDP, H1299, and H1299/DDP cells under different concentrations of DDP was analyzed by using the CCK8 assay to assess the IC50 value for DDP in cells. (b) Cell viability was detected by using the CCK8 assay under different concentrations of anlotinib to assess the IC50 value for anlotinib in A549/DDP and H1299/DDP cells. (c, d) A549/DDP and H1299/DDP cells were treated with 1 μ M anlotinib, 2 μ M DDP, or 1 μ M anlotinib + 2 μ M DDP. (c) Cell viability was measured by using the CCK8 assay. (d) Colony formation assay was used to assess A549/DDP and H1299/DDP cell proliferation. ∗∗ P < 0.01, ∗∗∗ P < 0.001.

Article Snippet: 24 h later, cells were treated with 1 μ M anlotinib, 2 μ M DDP, or 20 μ M ACT001 (Accendatech Co., Ltd., Tianjin, China) for 24 h.

Techniques: CCK-8 Assay, Colony Assay

Journal: Canadian Respiratory Journal

Article Title: Anlotinib Inhibits Cisplatin Resistance in Non-Small-Cell Lung Cancer Cells by Inhibiting MCL-1 Expression via MET/STAT3/Akt Pathway

doi: 10.1155/2024/2632014

Figure Lengend Snippet: Anlotinib inhibited MET to participate in the DDP resistance of NSCLC cells. (a) MET mRNA expression was detected by qRT-PCR in A549/DDP and H1299/DDP cells treated with or without anlotinib. (b) The p-MET/MET protein expression was examined by western blot analysis in A549/DDP and H1299/DDP cells treated with or without anlotinib. (c–g) A549/DDP and H1299/DDP cells were transfected with oe-MET and then treated with anlotinib and DDP. (c) MET mRNA expression was examined by qRT-PCR. (d) Western blot analysis was used to examine p-MET/MET protein expression. CCK8 assay (e), colony formation assay (f), and transwell assay (g) were used to assess cell viability, proliferation, migration, and invasion. ∗ P < 0.05, ∗∗ P < 0.01, and ∗∗∗ P < 0.001.

Article Snippet: 24 h later, cells were treated with 1 μ M anlotinib, 2 μ M DDP, or 20 μ M ACT001 (Accendatech Co., Ltd., Tianjin, China) for 24 h.

Techniques: Expressing, Quantitative RT-PCR, Western Blot, Transfection, CCK-8 Assay, Colony Assay, Transwell Assay, Migration

Journal: Canadian Respiratory Journal

Article Title: Anlotinib Inhibits Cisplatin Resistance in Non-Small-Cell Lung Cancer Cells by Inhibiting MCL-1 Expression via MET/STAT3/Akt Pathway

doi: 10.1155/2024/2632014

Figure Lengend Snippet: Effects of oe-MET and shMCL-1 on anlotinib-mediated DDP resistance in NSCLC cells. (a, b) A549/DDP and H1299/DDP cells were treated with 1 μ M anlotinib, 2 μ M DDP, or 1 μ M anlotinib+2 μ M DDP. (a) MET and MCL-1 mRNA expression was determined by qRT-PCR. (b) The p-MET/MET and MCL-1 protein expression was examined by western blot analysis. (c–g) A549/DDP and H1299/DDP cells were transfected with oe-MET-1 and sh-MCL-1, followed by treatment with 1 μ M anlotinib and 2 μ M DDP. (c) qRT-PCR was performed to examine MET and MCL-1 mRNA expression. (d) Western blot analysis was carried out to detect p-MET/MET and MCL-1 protein expression. Cell viability, proliferation, migration, and invasion were evaluated using the CCK8 assay (e), colony formation assay (f), and transwell assay (g). ∗ P < 0.05, ∗∗ P < 0.01, and ∗∗∗ P < 0.001.

Article Snippet: 24 h later, cells were treated with 1 μ M anlotinib, 2 μ M DDP, or 20 μ M ACT001 (Accendatech Co., Ltd., Tianjin, China) for 24 h.

Techniques: Expressing, Quantitative RT-PCR, Western Blot, Transfection, Migration, CCK-8 Assay, Colony Assay, Transwell Assay

Journal: Canadian Respiratory Journal

Article Title: Anlotinib Inhibits Cisplatin Resistance in Non-Small-Cell Lung Cancer Cells by Inhibiting MCL-1 Expression via MET/STAT3/Akt Pathway

doi: 10.1155/2024/2632014

Figure Lengend Snippet: Effects of oe-MET and ACT001 on anlotinib-mediated DDP resistance in NSCLC cells. A549/DDP and H1299/DDP cells were transfected with oe-MET-1 and then treated with anlotinib, DDP, and ACT001. (a) The mRNA expression levels of MET and MCL-1 were assessed by qRT-PCR. (b) The protein levels of p-MET/MET, p-STAT3/STAT3, p-Akt/Akt, and MCL-1 were measured by western blot analysis. CCK8 assay (c), colony formation assay (d), and transwell assay (e) were performed to examine cell viability, proliferation, migration, and invasion. ∗∗ P < 0.01 and ∗∗∗ P < 0.001.

Article Snippet: 24 h later, cells were treated with 1 μ M anlotinib, 2 μ M DDP, or 20 μ M ACT001 (Accendatech Co., Ltd., Tianjin, China) for 24 h.

Techniques: Transfection, Expressing, Quantitative RT-PCR, Western Blot, CCK-8 Assay, Colony Assay, Transwell Assay, Migration